This article is more than 5 years old. Information may no longer be current.
Surgical resection of extremity tumors after chemotherapy brings better results
Surgical resection of a primary tumor in the extremities following neoadjuvant chemotherapy leads to more positive results, according to recently published data.
Researchers conducted a retrospective review of 158 patients with a Ewing-family tumor of an extremity who received neoadjuvant chemotherapy, surgery and/or radiation therapy as local treatment, and then adjuvant chemotherapy. Mean age of patients was 15 years. Median follow-up time was 24.3 months.
Sixty-nine patients had observable metastatic disease, 57 underwent surgery and 41 received radiation therapy following neoadjuvant chemotherapy.
At follow-up, 5-year event-free survival rate was 24.1%, overall survival was 43.5% and local control rate was 55% for the entire cohort. Five-year event-free survival, overall survival and local control rates were 36.4%, 57.6%, and 58.2%, respectively, for patients without metastases.
Metastases was a significant predictor of inferior event-free survival (P = 0.02) and overall survival rates (P = 0.03) among the entire cohort, whereas radiation therapy significantly predicted inferior local control rate both overall (P = 0.001) and in patients without metastases (P = 0.04).
No significant difference in tumor diameter or response following neoadjuvant chemotherapy was observed between the patients with localized disease who underwent radiation therapy and those who underwent surgery, according to the study.
Disclosure: The authors have no relevant financial disclosures.